Drug models

We did focus on the Tucuxi core computing engine to make it as efficient as possible, while being generic enough to allow new models to be added without struggling with programming languages. Therefore the drug models are described in external files.

Below you find a list of current drug models that have been implemented by various people.

If you wish to create your own model, you are very welcome to use the drug model editor : https://drugeditor.tucuxi.ch . It allows to create your own model and ensures your model will give some results in Tucuxi.

  • Apixaban. Based on “Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation”, Cirincione B, Kowalski K, Frost C et al. .
  • Busulfan. Based on “Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation”, Paci A., Vassal G., Moshous D., Dalle J.H., Bleyzac N., Neven B., Galambrun C., Kemmel V., Abdi Z.D., Broutin S., Pétain A., Nguyen L. .
  • Cefepime. Based on a meta-analysis performed by Thierry Buclin.
  • Daptomycin. Based on “Population pharmacokinetics of daptomycin”, Dvorchik B. and Arbeit R.D., Chung J., Liu S., Knebel W., Kastrissios H. .
  • Darunavir. Based on “Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data”, Daskapan, Alper and Tran, Quynh T. D. and Cattaneo, Dario and Gervasoni, Cristina and Resnati, Chiara and Stienstra, Ymkje and Bierman, Wouter F. W. and Kosterink, Jos G. W. and van der Werf, Tjip S. and Proost, Johannes H. and Alffenaar, Jan-Willem C. and Touw, Daniel J.
  • Dolutegravir. Based on “Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting”, Catalina Barcelo, Manel Aouri, Perrine Courlet, Monia Guidi, Dominique L Braun, Huldrych F Günthard, Rein J Piso, Matthias Cavassini, Thierry Buclin, Laurent A Decosterd, Chantal Csajka, Swiss HIV Cohort Study.
  • Doravirine. Based on “Population pharmacokinetics of doravirine and exposure-response analysis in individuals with HIV-1”, Yee, K. L. and Ouerdani, A. and Claussen, A. and de Greef, R. and Wenning, L. .
  • Gentamicin. Based on “Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates”, Aline Fuchs and Monia Guidi and Eric Giannoni and Dominique Werner and Thierry Buclin and Nicolas Widmer and Chantal Csajka.
  • Imatinib. Based on “Therapeutic Drug Monitoring of Imatinib. Bayesian and Alternative Methods to Predict Trough Levels”, Verena Gotta, Nicolas Widmer, Michael Montemurro, Serge Leyvraz, Amina Haouala, Laurent A. Decosterd, Chantal Csajka and Thierry Buclin.
  • Lopinavir. Based on “Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study”, Fuchs, Aline and Rotzinger, Aurélie and Cavassini, Matthias and Bugnon, Olivier and Buclin, Thierry and Schneider, Marie Paule and Csajka, Chantal.
  • Meropenem. Based on “Population Pharmacokinetic Analysis and Dosing Regimen Optimization of Meropenem in Adult Patients”, Chonghua Li, Joseph L. Kuti, Charles H. Nightingale, David P. Nicolau.
  • Piperacillin. Based on “Development and validation of a clinical decision support tool for piperacillin”, Rong Chen, Qing Qian, Meng-ru Sun, Chun-yan Qian, Su-lan Zou, Ming-li Wang, Li-ying Wang.
  • Piperacillin. Based on “Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection”, Chonghua Li, Joseph L Kuti, Charles H Nightingale, Debra L Mansfield, Adrian Dana, David P Nicolau.
  • Ponatinib. Based on “Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model-Informed Dose Selection for Pediatric Development”, Michael J. Hanley, Paul M. Diderichsen, Narayana Narasimhan, Shouryadeep Srivastava, Neeraj Gupta, and Karthik Venkatakrishnan.
  • Rifampicin. Based on “A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses”, Robin J. Svensson, Rob E. Aarnoutse, Andreas H. Diacon, Rodney Dawson, Stephen H. Gillespie, Martin J. Boeree and Ulrika S.H. Simonsson.
  • Tacrolimus. Based on “Population Pharmacokinetic Modelling and Design of a Bayesian Estimator for Therapeutic Drug Monitoring of Tacrolimus in Lung Transplantation”, Caroline Monchaud, Brenda C. de Winter, Christiane Knoop, Marc Estenne, Martine Reynaud-Gaubert, Christophe Pison, Marc Stern, Romain Kessler, Romain Guillemain, Pierre Marquet and Annick Rousseau.
  • Teicoplanin. Based on “Population pharmacokinetics and pharmacodynamics of teicoplanin and C-reactive protein in hospitalized patients with Gram-positive infections”, Chika Ogami, Yasuhiro Tsuji, Yuichi Muraki, Akiko Mizoguchi, Masahiro Okuda, Hideto To.
  • Tobramycin. Based on “Population Pharmacokinetics of Tobramycin in Patients With and Without Cystic Fibrosis”, Stefanie Hennig, Joseph F. Standing, Christine E. Staatz, Alison H. Thomson.
  • Vancomycin. Based on “Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations”, Colin PJ, Allegaert K, Thomson AH, Touw DJ, Dolton M, de Hoog M, Roberts JA, Adane ED, Yamamoto M, Santos-Buelga D, Martín-Suarez A, Simon N, Taccone FS, Lo YL, Barcia E, Struys MMRF, Eleveld DJ.
  • Vancomycin. Based on “Optimisation of vancomycin exposure in neonates based on the best level of evidence”, Dao K, Guidi M, André P, Giannoni E, Basterrechea S, Zhao W, Fuchs A, Pfister M, Buclin T, Csajka C.
  • Vancomycin. Based on “Hospitalized Patients With and Without Hemodialysis Have Markedly Different Vancomycin Pharmacokinetics: A Population Pharmacokinetic Model-Based Analysis”, Vineet Goti, Ayyappa Chaturvedula, Michael J. Fossler, Steve Mok and Jesse T. Jacob.
  • Vancomycin. Based on “A population pharmacokinetic model of vancomycin for dose individualization based on serum cystatin C as a marker of renal function”, Tao-tao Liua , Hui-mei Panga, Li Jinga, Wen-xing Weia, Xiao-ling Qina, Qing Guoa, Hua Lua,Dao-hai Chenga and Wei-zhe Jiang.
  • Vancomycin. Based on “Population pharmacokinetic parameters of vancomycin in critically ill patients”, Llopis-Salvia, P. and Jiménez-Torres, N. V. .
  • Vancomycin. Based on “Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery”, Staatz, Christine E. and Byrne, Colette and Thomson, Alison H. .
  • Vancomycin. Based on “Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations”, A.H. Thomson, C.E. Staatz, C.M. Tobin, M. Gall, A.M. Lovering.
  • Vancomycin. Based on “Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type”, Yamamoto, M. and Kuzuya, T. and Baba, H. and Yamada, K. and Nabeshima, T. .